Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Landmark Malaria Vaccine Pilot Launches In Malawi

The first ever malaria vaccine is being launched in three African countries in an effort to gather more evidence about how it should be used in real life settings.

Middle East and Africa Malawi

NICE Says Yes To Akcea’s Tegsedi After ‘Improved’ Commercial Offer

NICE has given the green light to Akcea Therapeutics’ ultra-rare disease treatment Tegsedi (inotersen) after the company offered a better “commercial arrangement.”

Europe United Kingdom

Annuity-Based Pricing Models Could Mean Problems For Small Biotechs

Interest in annuity payment models is growing among companies and payers, but such models could be risk financial viability of small biotechs.

Reimbursement Regenerative Medicine

Annuity Payments For Costly One-Off Drugs Is No Magic Bullet

Paying for expensive one-off treatments in installments rather than one lump sum could be appropriate for some products, but fails to address wider systemic problems.

Gene Therapy Market Access

Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer

Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a meeting on the drug after a large number of comments were received following the institute’s initial knockback.

Europe United Kingdom

Combination Pricing Solution As Elusive As Ever

The pricing of combination therapies, particularly in oncology, remains a headache for payers and companies.

Market Access Policy
See All
Advertisement
UsernamePublicRestriction

Register